Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complementary and alternative medicine for advanced prostate cancer.

J Daniell Rackley1, Peter E Clark, M Craig Hall

  • 1Department of Urology, Wake Forest University School of Medicine, Comprehensive Cancer Center, Winston-Salem, NC 27157-1094, USA.

The Urologic Clinics of North America
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

European urology·2026
Same author

Racial and socioeconomic disparities from time of diagnosis to treatment for small renal masses.

BJUI compass·2026
Same author

Protocol-driven same day discharge for robotic radical prostatectomy.

Urologic oncology·2025
Same author

Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort.

Urologic oncology·2024
Same author

Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.

Scientific reports·2024
Same author

Reply by Authors.

Urology practice·2024
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Complimentary and alternative medicines (CAM) are popular but lack evidence. This review examines scientific data for common CAM nutritional supplements used in advanced prostate cancer care.

Area of Science:

  • Oncology
  • Nutritional Science
  • Integrative Medicine

Background:

  • Complimentary and alternative medicines (CAM), particularly nutritional supplements, have surged in popularity.
  • A significant challenge with CAM is the limited evidence-based medical data supporting their efficacy.
  • Advanced prostate cancer presents long-term morbidity, driving patient interest in less toxic therapies.

Purpose of the Study:

  • To review the scientific evidence supporting the use of common CAM nutritional supplements.
  • To assess the potential role of these supplements in managing advanced or recurrent prostate cancer.
  • To provide clinicians and patients with data on CAM therapies for prostate cancer.

Main Methods:

  • Literature review of scientific data on popular CAM nutritional supplements.

Related Experiment Videos

  • Analysis of studies investigating CAM efficacy and safety in advanced prostate cancer.
  • Summarization of evidence-based findings for selected supplements.

    • Main Results:

    • Evidence supporting many common CAM nutritional supplements for advanced prostate cancer is limited.
    • Some supplements show preliminary promise, but robust clinical trial data are often lacking.
    • The review highlights the need for critical evaluation of CAM claims in oncology.

    Conclusions:

    • CAM nutritional supplements are widely used, but scientific validation for advanced prostate cancer is often insufficient.
    • Further rigorous research is needed to establish the safety and efficacy of CAM in prostate cancer treatment.
    • A balanced approach integrating evidence-based medicine with patient-centered care is crucial.